170 related articles for article (PubMed ID: 36273464)
21. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
22. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH; Tobin JWD; Seo YD; Gener-Ricos G; Keung EZ; Burton EM; Davies MA; McQuade JL; Lazar AJ; Mason R; Millward M; Sandhu S; Khoo C; Warburton L; Guerra V; Haydon A; Dearden H; Menzies AM; Carlino MS; Smith JL; Mollee P; Burgess M; Mapp S; Keane C; Atkinson V; Parikh SA; Markovic SN; Ding W; Call TG; Hampel PJ; Long GV; Wargo JA; Ferrajoli A
Ann Oncol; 2023 Sep; 34(9):796-805. PubMed ID: 37414216
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Therapies for Melanoma.
Buchbinder EI
Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
[TBL] [Abstract][Full Text] [Related]
26. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
27. Leveraging big data of immune checkpoint blockade response identifies novel potential targets.
Bareche Y; Kelly D; Abbas-Aghababazadeh F; Nakano M; Esfahani PN; Tkachuk D; Mohammad H; Samstein R; Lee CH; Morris LGT; Bedard PL; Haibe-Kains B; Stagg J
Ann Oncol; 2022 Dec; 33(12):1304-1317. PubMed ID: 36055464
[TBL] [Abstract][Full Text] [Related]
28. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
29. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
30. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
31. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
32. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
34. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
35. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
[TBL] [Abstract][Full Text] [Related]
36. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
37. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
38. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG; Huppert LA; Daud AI
Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]